Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog
Choi J, Gao W, Odegard J, Shiah H, Kashgarian M, McNiff JM, Baker DC, Cheng Y, Craft J. Abrogation of skin disease in LUPUS‐prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis & Rheumatism 2006, 54: 3277-3283. PMID: 17009262, DOI: 10.1002/art.22119.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEnd-organ diseaseInflammatory skin diseaseMRL/Skin diseasesMRL/Faslpr miceFemale MRL/NF-kappaB inhibitorFlow cytometric analysisFaslpr miceAutoantibody titersIgG levelsLupus erythematosusLymph nodesRenal diseaseVehicle treatmentKidney diseaseHepatic toxicityTotal IgMTylophorine analogsAntichromatin autoantibodiesTherapeutic effectHistopathologic analysisMurine modelSignificant abrogation